Literature DB >> 21676964

Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece.

Evangelos Liberopoulos1, Fotini Vlasserou, Zoe Mitrogianni, Ioannis Papageorgantas, Moses Elisaf.   

Abstract

Many statin-treated patients are not achieving treatment goals and are at risk of cardiovascular (CV) disease. We report the results of patients enrolled in an observational study in Greece, which estimated the residual lipid abnormalities in statin-treated patients. Low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and triglyceride concentrations were recorded in patients receiving statin therapy for ≥ 3 months, classified by CV risk according to European Society of Cardiology guidelines. Sixty-three percent of statin-treated patients had an LDL-c not at goal. Low-risk patients were more likely to have an LDL-c not at goal compared with high-risk patients (67.3% vs 61.0%, respectively). They were also less likely to have low HDL-c levels and elevated triglyceride levels compared with high-risk patients. Smoking and sedentary lifestyle were not associated with dyslipidemia in this population. Approximately two thirds of statin-treated patients in Greece are not reaching target/normal lipid levels and could benefit from improved lipid management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21676964     DOI: 10.1177/0003319711410226

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  5 in total

1.  Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions.

Authors:  Anastazia Kei; Evangelos Liberopoulos; Costantinos Tellis; Moses Elisaf; Alexandros Tselepis
Journal:  Lipids       Date:  2013-08-15       Impact factor: 1.880

2.  Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II.

Authors:  Evangelos Liberopoulos; Loukianos Rallidis; Filio Spanoudi; Elena Xixi; Anselm Gitt; Martin Horack; Veronica Ashton; Philippe Brudi; Dominik Lautsch; Baishali Ambegaonkar; Moses Elisaf
Journal:  Arch Med Sci       Date:  2018-03-12       Impact factor: 3.318

3.  Assessing forgetfulness and polypharmacy and their impact on health-related quality of life among patients with hypertension and dyslipidemia in Greece during the COVID-19 pandemic.

Authors:  Kyriakos Souliotis; Theodoros V Giannouchos; Chistina Golna; Evangelos Liberopoulos
Journal:  Qual Life Res       Date:  2021-06-22       Impact factor: 3.440

4.  Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study.

Authors:  Sami T Azar; Hadi Abu Hantash; Selim Jambart; Mohamed M El-Zaheri; Rachoin Rachoin; Amal Chalfoun; Layla Lahoud; Osama Okkeh; Peter Bramlage; Philippe Brudi; Baishali M Ambegaonkar
Journal:  Vasc Health Risk Manag       Date:  2014-05-07

5.  Residual Dyslipidemia Leads to Unfavorable Outcomes in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention.

Authors:  Bin Que; Chunmei Wang; Hui Ai; Xinyong Zhang; Mei Wang; Shaoping Nie
Journal:  Stem Cells Int       Date:  2016-01-06       Impact factor: 5.443

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.